Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jan;39(1):45–49. doi: 10.1128/aac.39.1.45

Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis.

R Malinverni 1, C C Kuo 1, L A Campbell 1, A Lee 1, J T Grayston 1
PMCID: PMC162482  PMID: 7695327

Abstract

We studied the effects of two antibiotic regimens on the course of Chlamydia pneumoniae infection in the lungs of Swiss Webster mice. After intranasal challenge with isolates AR-388 (1.3 x 10(7) inclusion-forming units per mouse) and AR-39 (1.5 x 10(6) inclusion-forming units per mouse), groups of animals were treated with either doxycycline (10 mg/kg of body weight once a day for 3 days), azithromycin (10 mg/kg [single dose]), or saline. Responses were assessed by the isolation of organisms in cell culture, detection of TWAR DNA in lung tissues by PCR, and lung histology. Both regimens were effective in clearing infections induced by AR-388 (P = 0.02 and 0.007 for doxycycline and azithromycin, respectively) compared with controls. TWAR DNA was detected in 77 and 25% of culture-negative lungs 2 weeks after treatment of AR-388 and AR-39 infections, respectively. Histological changes showed interstitial pneumonitis and were similar over time for all groups. Single-dose azithromycin produced drug levels in lung tissues above the MICs for the test strains for a period three times longer than that of single-dose doxycycline. We concluded that short-term antibiotic regimens were successful for the treatment of experimental TWAR pneumonitis in mice. TWAR DNA was frequently recovered from lung tissues after apparently successful treatment.

Full Text

The Full Text of this article is available as a PDF (187.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belli G., Ciaffi G., Ricci P. Livelli ematici e tessutali di due antibiotici del gruppo delle tetracicline somministrati nell'uomo per via orale. Antibiotica. 1968 Jun;6(2):109–115. [PubMed] [Google Scholar]
  2. Bobo L., Munoz B., Viscidi R., Quinn T., Mkocha H., West S. Diagnosis of Chlamydia trachomatis eye infection in Tanzania by polymerase chain reaction/enzyme immunoassay. Lancet. 1991 Oct 5;338(8771):847–850. doi: 10.1016/0140-6736(91)91502-l. [DOI] [PubMed] [Google Scholar]
  3. Bowman P., Wilt J. C., Sayed H. Chronicity and recurrence of psittacosis. Can J Public Health. 1973 Mar;64(2):167–173. [PubMed] [Google Scholar]
  4. Campbell L. A., Perez Melgosa M., Hamilton D. J., Kuo C. C., Grayston J. T. Detection of Chlamydia pneumoniae by polymerase chain reaction. J Clin Microbiol. 1992 Feb;30(2):434–439. doi: 10.1128/jcm.30.2.434-439.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cappuccio A. L., Patton D. L., Kuo C. C., Campbell L. A. Detection of Chlamydia trachomatis deoxyribonucleic acid in monkey models (Macaca nemestrina) of salpingitis by in situ hybridization: implications for pathogenesis. Am J Obstet Gynecol. 1994 Jul;171(1):102–110. doi: 10.1016/s0002-9378(94)70085-0. [DOI] [PubMed] [Google Scholar]
  6. Cheema M. A., Schumacher H. R., Hudson A. P. RNA-directed molecular hybridization screening: evidence for inapparent chlamydial infection. Am J Med Sci. 1991 Nov;302(5):261–268. doi: 10.1097/00000441-199111000-00001. [DOI] [PubMed] [Google Scholar]
  7. Cunha B. A., Comer J. B., Jonas M. The tetracyclines. Med Clin North Am. 1982 Jan;66(1):293–302. doi: 10.1016/s0025-7125(16)31461-4. [DOI] [PubMed] [Google Scholar]
  8. Ekman M. R., Grayston J. T., Visakorpi R., Kleemola M., Kuo C. C., Saikku P. An epidemic of infections due to Chlamydia pneumoniae in military conscripts. Clin Infect Dis. 1993 Sep;17(3):420–425. doi: 10.1093/clinids/17.3.420. [DOI] [PubMed] [Google Scholar]
  9. Fang G. D., Fine M., Orloff J., Arisumi D., Yu V. L., Kapoor W., Grayston J. T., Wang S. P., Kohler R., Muder R. R. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) 1990 Sep;69(5):307–316. doi: 10.1097/00005792-199009000-00004. [DOI] [PubMed] [Google Scholar]
  10. Foulds G., Shepard R. M., Johnson R. B. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):73–82. doi: 10.1093/jac/25.suppl_a.73. [DOI] [PubMed] [Google Scholar]
  11. Girard A. E., Girard D., Retsema J. A. Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):61–71. doi: 10.1093/jac/25.suppl_a.61. [DOI] [PubMed] [Google Scholar]
  12. Grayston J. T., Aldous M. B., Easton A., Wang S. P., Kuo C. C., Campbell L. A., Altman J. Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis. J Infect Dis. 1993 Nov;168(5):1231–1235. doi: 10.1093/infdis/168.5.1231. [DOI] [PubMed] [Google Scholar]
  13. Grayston J. T., Campbell L. A., Kuo C. C., Mordhorst C. H., Saikku P., Thom D. H., Wang S. P. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis. 1990 Apr;161(4):618–625. doi: 10.1093/infdis/161.4.618. [DOI] [PubMed] [Google Scholar]
  14. Grayston J. T., Wang S. P., Yeh L. J., Kuo C. C. Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis. 1985 Nov-Dec;7(6):717–725. doi: 10.1093/clinids/7.6.717. [DOI] [PubMed] [Google Scholar]
  15. Hammerschlag M. R. Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae. Antimicrob Agents Chemother. 1994 Sep;38(9):1873–1878. doi: 10.1128/aac.38.9.1873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hammerschlag M. R., Chirgwin K., Roblin P. M., Gelling M., Dumornay W., Mandel L., Smith P., Schachter J. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis. 1992 Jan;14(1):178–182. doi: 10.1093/clinids/14.1.178. [DOI] [PubMed] [Google Scholar]
  17. Hammerschlag M. R., Qumei K. K., Roblin P. M. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992 Jul;36(7):1573–1574. doi: 10.1128/aac.36.7.1573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Holland S. M., Hudson A. P., Bobo L., Whittum-Hudson J. A., Viscidi R. P., Quinn T. C., Taylor H. R. Demonstration of chlamydial RNA and DNA during a culture-negative state. Infect Immun. 1992 May;60(5):2040–2047. doi: 10.1128/iai.60.5.2040-2047.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hudson A. P., McEntee C. M., Reacher M., Whittum-Hudson J. A., Taylor H. R. Inapparent ocular infection by Chlamydia trachomatis in experimental and human trachoma. Curr Eye Res. 1992 Mar;11(3):279–283. doi: 10.3109/02713689209001780. [DOI] [PubMed] [Google Scholar]
  20. Kuo C. C., Chen H. H., Wang S. P., Grayston J. T. Identification of a new group of Chlamydia psittaci strains called TWAR. J Clin Microbiol. 1986 Dec;24(6):1034–1037. doi: 10.1128/jcm.24.6.1034-1037.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kuo C. C., Gown A. M., Benditt E. P., Grayston J. T. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb. 1993 Oct;13(10):1501–1504. doi: 10.1161/01.atv.13.10.1501. [DOI] [PubMed] [Google Scholar]
  22. Kuo C. C., Grayston J. T. A sensitive cell line, HL cells, for isolation and propagation of Chlamydia pneumoniae strain TWAR. J Infect Dis. 1990 Sep;162(3):755–758. doi: 10.1093/infdis/162.3.755. [DOI] [PubMed] [Google Scholar]
  23. Kuo C. C., Grayston J. T. In vitro drug susceptibility of Chlamydia sp. strain TWAR. Antimicrob Agents Chemother. 1988 Feb;32(2):257–258. doi: 10.1128/aac.32.2.257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kuo C. C., Shor A., Campbell L. A., Fukushi H., Patton D. L., Grayston J. T. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 1993 Apr;167(4):841–849. doi: 10.1093/infdis/167.4.841. [DOI] [PubMed] [Google Scholar]
  25. Linnanmäki E., Leinonen M., Mattila K., Nieminen M. S., Valtonen V., Saikku P. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation. 1993 Apr;87(4):1130–1134. doi: 10.1161/01.cir.87.4.1130. [DOI] [PubMed] [Google Scholar]
  26. Marrie T. J. Community-acquired pneumonia. Clin Infect Dis. 1994 Apr;18(4):501–515. doi: 10.1093/clinids/18.4.501. [DOI] [PubMed] [Google Scholar]
  27. Marrie T. J., Grayston J. T., Wang S. P., Kuo C. C. Pneumonia associated with the TWAR strain of Chlamydia. Ann Intern Med. 1987 Apr;106(4):507–511. doi: 10.7326/0003-4819-106-4-507. [DOI] [PubMed] [Google Scholar]
  28. Martin D. H., Mroczkowski T. F., Dalu Z. A., McCarty J., Jones R. B., Hopkins S. J., Johnson R. B. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group. N Engl J Med. 1992 Sep 24;327(13):921–925. doi: 10.1056/NEJM199209243271304. [DOI] [PubMed] [Google Scholar]
  29. Melnick S. L., Shahar E., Folsom A. R., Grayston J. T., Sorlie P. D., Wang S. P., Szklo M. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Med. 1993 Nov;95(5):499–504. doi: 10.1016/0002-9343(93)90332-j. [DOI] [PubMed] [Google Scholar]
  30. Patton D. L., Askienazy-Elbhar M., Henry-Suchet J., Campbell L. A., Cappuccio A., Tannous W., Wang S. P., Kuo C. C. Detection of Chlamydia trachomatis in fallopian tube tissue in women with postinfectious tubal infertility. Am J Obstet Gynecol. 1994 Jul;171(1):95–101. doi: 10.1016/s0002-9378(94)70084-2. [DOI] [PubMed] [Google Scholar]
  31. Patton D. L., Cosgrove Y. T., Kuo C. C., Campbell L. A. Effects of quinolone analog CI-960 in a monkey model of Chlamydia trachomatis salpingitis. Antimicrob Agents Chemother. 1993 Jan;37(1):8–13. doi: 10.1128/aac.37.1.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Patton D. L., Sweeney Y. T., Kuo C. C. Demonstration of delayed hypersensitivity in Chlamydia trachomatis salpingitis in monkeys: a pathogenic mechanism of tubal damage. J Infect Dis. 1994 Mar;169(3):680–683. doi: 10.1093/infdis/169.3.680. [DOI] [PubMed] [Google Scholar]
  33. Peters D. H., Friedel H. A., McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1992 Nov;44(5):750–799. doi: 10.2165/00003495-199244050-00007. [DOI] [PubMed] [Google Scholar]
  34. Saikku P., Leinonen M., Mattila K., Ekman M. R., Nieminen M. S., Mäkelä P. H., Huttunen J. K., Valtonen V. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988 Oct 29;2(8618):983–986. doi: 10.1016/s0140-6736(88)90741-6. [DOI] [PubMed] [Google Scholar]
  35. Saikku P., Leinonen M., Tenkanen L., Linnanmäki E., Ekman M. R., Manninen V., Mänttäri M., Frick M. H., Huttunen J. K. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992 Feb 15;116(4):273–278. doi: 10.7326/0003-4819-116-4-273. [DOI] [PubMed] [Google Scholar]
  36. Sanders L. L., Jr, Harrison H. R., Washington A. E. Treatment of sexually transmitted chlamydial infections. JAMA. 1986 Apr 4;255(13):1750–1756. [PubMed] [Google Scholar]
  37. Schachter J., Moncada J., Dawson C. R., Sheppard J., Courtright P., Said M. E., Zaki S., Hafez S. F., Lorincz A. Nonculture methods for diagnosing chlamydial infection in patients with trachoma: a clue to the pathogenesis of the disease? J Infect Dis. 1988 Dec;158(6):1347–1352. doi: 10.1093/infdis/158.6.1347. [DOI] [PubMed] [Google Scholar]
  38. Shepard R. M., Duthu G. S., Ferraina R. A., Mullins M. A. High-performance liquid chromatographic assay with electrochemical detection for azithromycin in serum and tissues. J Chromatogr. 1991 Apr 19;565(1-2):321–337. doi: 10.1016/0378-4347(91)80393-q. [DOI] [PubMed] [Google Scholar]
  39. Shor A., Kuo C. C., Patton D. L. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J. 1992 Sep;82(3):158–161. [PubMed] [Google Scholar]
  40. Tartaglione T. A., Taylor T. O., Opheim K. E., See W. A., Berger R. E. Antimicrobial tissue penetration in a rat model of E. coli epididymitis. J Urol. 1991 Nov;146(5):1413–1417. doi: 10.1016/s0022-5347(17)38126-0. [DOI] [PubMed] [Google Scholar]
  41. Thom D. H., Grayston J. T. Infections with Chlamydia pneumoniae strain TWAR. Clin Chest Med. 1991 Jun;12(2):245–256. [PubMed] [Google Scholar]
  42. Thom D. H., Grayston J. T., Siscovick D. S., Wang S. P., Weiss N. S., Daling J. R. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA. 1992 Jul 1;268(1):68–72. [PubMed] [Google Scholar]
  43. Thom D. H., Wang S. P., Grayston J. T., Siscovick D. S., Stewart D. K., Kronmal R. A., Weiss N. S. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb. 1991 May-Jun;11(3):547–551. doi: 10.1161/01.atv.11.3.547. [DOI] [PubMed] [Google Scholar]
  44. Welsh L. E., Gaydos C. A., Quinn T. C. In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992 Feb;36(2):291–294. doi: 10.1128/aac.36.2.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Yang Z. P., Kuo C. C., Grayston J. T. A mouse model of Chlamydia pneumoniae strain TWAR pneumonitis. Infect Immun. 1993 May;61(5):2037–2040. doi: 10.1128/iai.61.5.2037-2040.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES